Acyl derivatives which treat vla-4 related disorders
CA 2359115 C · Owner: Welmaker, Gregory S. · Inventors: Dressen, Darren B.; Welmaker, Gregory S.; Pleiss, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds such as IIa which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g. human, such as asthma Alzheimer's disease, atherosclerosis, AIDS dementia diabetes, inflammatory , bowel disease rheumatoid arthritis, tissue transplantation tumor metastasis , and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiples sclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 21, 2000 and granted June 21, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 21, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 21, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.